Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine BiopharmaSBFM +0.87%34 Earnings Yield (Joel Greenblatt) % is 71.94% as of Jun. 2026, which is 31% below its 10-year median of 103.96. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $2.49 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Sunshine Biopharma ranks worse than 99304.77% on this metric.
Sunshine Biopharma's Enterprise Value for the quarter that ended in Jun. 2026 was $-8.04 Mil.
Sunshine Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-5.76 Mil. Sunshine Biopharma's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 71.94%.
The historical rank and industry rank for Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SBFM'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2580.66 Med: 103.96 Max: 5656.2
Current: 67.11
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Sunshine Biopharma was 5656.20%. The lowest was -2580.66%. And the median was 103.96%.
SBFM's Earnings Yield (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.25
vs SBFM: 67.11
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sunshine Biopharma's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sunshine Biopharma Earnings Yield (Joel Greenblatt) % Related Terms
Sunshine Biopharma Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sunshine Biopharmas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Sunshine Biopharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.76 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 71.94% mean?
Sunshine Biopharma (SBFM) has a Earnings Yield (Joel Greenblatt) % of 71.94% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sunshine Biopharma and its competitors. This is 31% below median its historical median of 103.96. According to the industry distribution chart, Sunshine Biopharma ranks #999999 out of 1007 companies in the Drug Manufacturers industry.
Is Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % too high?
Sunshine Biopharma's current Earnings Yield (Joel Greenblatt) % of 71.94% is 31% below median its 10-year median of 103.96. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.25. Sunshine Biopharma's value of 71.94% is 2113.5% above this industry median. Based on the distribution chart, Sunshine Biopharma ranks #999999 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % compare to PRFX and BUDZ?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #999999 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This places Sunshine Biopharma in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.25. Sunshine Biopharma's value of 71.94% is 2113.5% above this benchmark. While the company's 10-year median is 103.96 vs. the industry median of 3.25, Sunshine Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.25, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Biopharma's current Earnings Yield (Joel Greenblatt) % of 71.94% is 2113.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current Earnings Yield (Joel Greenblatt) % is 71.94%, which is 31% below median its own 10-year median of 103.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.49, compared to a current price of $1.16 — trading 53.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 71.94%, which is 31% below median its 10-year median of 103.96 and 2113.5% above the Drug Manufacturers industry median of 3.25. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current Earnings Yield (Joel Greenblatt) % is 71.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Biopharma (SBFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued.
The current stock price of $1.16 is trading 53.4% below its estimated GF Value™ of $2.49.
GuruFocus considers Sunshine Biopharma to be Possible Value Trap.
Key valuation signals for SBFM:
Earnings Yield (Joel Greenblatt) %: 71.94% (31% below median its 10-year median of 103.96)
GF Value™: $2.49 vs. price of $1.16 (53.4% below fair value)
Industry Position: 2113.5% above the Drug Manufacturers median (#999999 of 1007)
No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFM
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFM has been successfully added to your 
